Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa

X
Trial Profile

A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabinol (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors InMed Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2023 According to a InMed Pharmaceuticals media release, full data and results of the Phase 2 clinical trial will be published shortly in Itch, the official journal of the International Forum for the Study of Itch (IFSI).
    • 14 Nov 2023 According to a InMed Pharmaceuticals media release, the company recently gave an oral presentation of an abstract describing the Phase 2 clinical study at the 12th World Congress on Itch (WCI) 2023.
    • 07 Nov 2023 According to a InMed Pharmaceuticals media release, data from this study presented in 12th World Congress on Itch (WCI)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top